Feature | March 17, 2015

Five-Year Outcomes for High-Risk Sapien Patients Demonstrate Equivalence To Surgery

PARTNER trial results indicate use for transcatheter aortic valve beyond inoperable patients

Edwards, Sapien, PARTNER trial, five-year outcomes, ACC

March 17, 2015 — Five-year data suggest that the Sapien transcatheter heart valve (Edwards Lifesciences) is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart surgery, though valve leakage was more common with the first-generation valve evaluated in this study than with surgery, according to research from PARTNER I presented at the American College of Cardiology’s (ACC) 2015 Annual Scientific Session. 

The final final five-year clinical data for high-risk patients treated with the first-generation Sapien transcatheter aortic valve in The PARTNER Trial demonstrated equivalent outcomes to traditional open-heart surgery. There was also no structural valve deterioration requiring intervention. Data from the prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients at high risk for surgery were presented as part of the late-breaking clinical trials at ACC and simultaneously published in The Lancet.

"It's remarkable that this five-year data report continues to show equivalency between what was then a brand new procedure with a first-generation TAVR device and the gold standard of surgery, which has been honed over 50 years of experience," said Michael Mack, M.D., chair, cardiovascular service line, Baylor Scott and White Health.  "Just as we observed in the five-year report from The PARTNER Trial on outcomes in inoperable patients treated with Sapien, the high-risk patients also had durable valve performance. These data show that TAVR is an effective treatment for these patients."  

The authors noted no significant differences in all-cause mortality, cardiovascular mortality, stroke or need for repeat hospitalization. 

“The surprise is that there were no surprises,” Mack said. “The findings at five years confirm the earlier findings that outcomes are equivalent in high-risk surgical patients with surgery and with TAVR.” There were no signs of structural valve deterioration or loss of valve function with TAVR, he said.

The high-risk surgery cohort (Cohort A) of The PARTNER Trial enrolled between May 2007 and September 2009 and studied 699 patients with severe, symptomatic aortic stenosis deemed at high risk for traditional open-heart surgery. Patients were evaluated by a multidisciplinary heart team and randomized to receive either traditional open-heart surgery or the Edwards Sapien valve with transfemoral or transapical delivery. This trial represented the initial TAVR experience for most trial sites in the United States.

At five years, death and stroke rates were statistically the same in both groups: 67.8 percent of TAVR patients and 62.4 percent of surgery patients had died, with median survival of 44.5 months with TAVR and 40.6 months with surgery. Stroke rates were 15.9 percent for TAVR patients and 14.7 percent for surgery patients. Rehospitalization rates and functional outcomes also were the same in both groups.

Transcatheter valves have not approached the low leakage rate around the valve that can be achieved by an open-heart operation. As in previous findings, the rate of moderate or severe leaking around the valve remained significantly higher for the TAVR group — 14 percent with TAVR and 2.1 percent with surgery — and at five years, that higher leakage rate still led to an increase in deaths with the death rate in patients with leakage 9 percent greater than in patients who didn’t have a significant leak. The firstgeneration valve used in this trial has already been replaced by a second-generation device that is approved in the United States, and a third-generation valve has been designed specifically to reduce leakage. Thirty-day results for the third-generation valve will be reported separately at the ACC meeting.

Data analysis identified several indications and cautions for both procedures. Kidney disease was a significant issue with TAVR but not surgery; a high Society of Thoracic Surgeons risk score, which indicates the patient is sicker at the time of treatment, was a predictor of death in the surgery group; and liver disease was a significant factor in both groups. TAVR patients will be followed annually for life in the Society of Thoracic Surgeons/ACC Transcatheter Valve Therapies registry; surgery patients will not be followed beyond five years.

The U.S. Food and Drug Administration (FDA) approved the Sapien valve in November 2011 for the treatment of inoperable patients, and expanded the indication to high-risk surgical patients in October 2012. In June 2014, the FDA approved the next-generation Sapien XT valve for the treatment of both inoperable and high-risk patients. 

For more information: acc.org, www.edwards.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init